Global Circulating Tumor Cells Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

Growing prevalence of cancer has heightened the need for effective and early diagnosis. Circulating tumor cells cater to this heightened need and are therefore, expected to witness a surge in demand during the forecast period. Majority of cancer deaths are due to circulating tumor cells and an early diagnosis of the same is expected to increase survival rates. Targeted therapy in cancer has large untapped opportunities and therefore, entails extensive R&D investments aimed at new product development. However, high procedure costs and lack of commercialized products are expected to impede market growth during the forecast period.

Further key findings from the study suggest:

• Application of alterations in the expression profiles of EMT-associated transcriptional regulators and their molecular targets as biomarkers in EMT study is expected to serve as an impetus for diagnosis of tumor
• North America led the CTC market in 2018 due to rising cases of cancer, oncology research funding, and favorable government initiatives for clinical diagnostic products
• APAC is anticipated to witness the highest CAGR of over 16% from 2019 to 2025 due to infrastructural development in care centers and increased sales of CTC diagnostic tests
• Rising need for new diagnosis methods for cancer has encouraged R&D in developing economies of APAC. This will help expand the region further
• Fluxion Biosciences, Inc.; AdnaGen AG; Biocept, Inc.; Ikonisys, Inc.; and Sysmex Corp. are some of the key industry participants
• Key companies focus on the development of novel technologies for CTC enrichment & detection through collaborations with hospitals and university-based research institutes to gain access to target population

Segmentation: